The Interagency Autism Coordinating Committee has reportedly adopted a three-year federal autism strategic roadmap that would seek substantially higher spending on services and research, while proposing studies and living models that have drawn objections from autism researchers and disability advocates.
The Guardian reported Aug. 28 that the committee, whose membership was remade by Health and Human Services Secretary Robert F. Kennedy Jr., approved the 336-page plan after a public-comment period. The reported action could help shape federal autism research and service priorities, but it does not itself appropriate money, award grants or alter medical care. No official IACC roadmap, adoption notice or voting record was available in the cited public sources.
An advisory plan, not a funding decision
According to The Guardian’s account, the roadmap sets an annual target of $760 million for autism services and $270 million for research. The research total includes a proposed $15 million for folate-biology studies. Those figures describe goals in an advisory plan, not enacted spending. As an advisory plan, the targets would require subsequent appropriations and agency action before they could affect federal spending.
The distinction is consequential because strategic plans can influence which questions agencies prioritize, yet they are not evidence that a particular intervention works or that a research hypothesis has been proved. Dr. Dan Rossignol, an IACC member quoted in the report, said the panel has no grant-making authority. He also said research funded in response to the plan would be independent of his medical center and Eletala, a company associated with a folate-related product, and that disclosure and ethics procedures had been followed.
The reported roadmap places services alongside biomedical research. That combination reflects a long-running disagreement over whether federal autism policy should concentrate more heavily on supports such as housing, communication access, education and employment, or direct more resources toward studies of biological pathways and possible contributors to autism. In practice, those aims need not be mutually exclusive, but the distribution of limited funds can determine what is studied and what kinds of assistance are available.
Research proposals leave major evidence questions open
Several provisions described in the report are proposals for further study, not clinical findings. The plan calls for controlled trials of fecal microbiota transplantation for autistic people who also have gastrointestinal problems, while recognizing that there is not enough knowledge to present it as a general autism intervention. No trial protocol, participant target, safety monitoring plan, endpoints or results were available in the cited sources.
The same caution applies to folate-related research. Helen Tager-Flusberg, an autism researcher quoted by The Guardian, said the proposed $15 million allocation was out of step with the field and that there was no evidence autistic people generally have a problem metabolizing folate. That is a criticism of the proposed research emphasis, not a finding that research on specific, clinically defined folate disorders should never be conducted. The available sources do not include a systematic review or regulator record that could establish the effectiveness or safety of leucovorin or other folate-related treatments for autism broadly.
Concerns also extend to partner-assisted communication, in which another person helps an autistic person communicate. The Independent Autism Coordinating Committee told The Guardian that rigorous studies have found that the assistant’s thoughts and words, rather than those of the autistic person, are conveyed. The article does not provide the underlying studies, and the reported roadmap language was not independently available for review. Still, the dispute illustrates why a call to investigate or use an approach should not be treated as validation of it.
Advocates raised a separate civil-rights concern about supported-living proposals, including farmstead-style settings. The Autistic Self Advocacy Network told the newspaper that such models could increase institutional placement and that farmsteads separate disabled people from non-disabled people. That is the group’s assessment of the models; the available reporting does not establish that the roadmap mandates institutional placement or identifies how any future programs would be designed.
Vaccine language adds to the scientific and policy dispute
The roadmap arrives after a notable change in the federal presentation of vaccine-autism research. A CDC webpage updated July 22 says HHS has begun what it calls a comprehensive assessment of autism causes, including potential causal links involving vaccines. The page says observational evidence on MMR vaccination and autism spectrum disorders shows no association, while also arguing that previous categorical statements about vaccines and autism did not account for the possibility of a contribution from infant vaccines.
That language differs sharply from the account offered by many autism organizations and researchers. In an April 2025 statement, the Autism Society of America said claims linking vaccines to autism had been debunked through decades of global research involving millions of people. The Guardian characterized the MMR-autism claim as false and reported that researchers feared the new roadmap could elevate anti-vaccine views.
The difference is more than semantic. The CDC page separates its discussion of MMR from its broader discussion of infant vaccines, whereas the Autism Society describes the larger vaccine-autism claim as disproved. Neither the reported roadmap nor the CDC webpage is a new clinical or epidemiological study. A federal decision to investigate a possible relationship would not demonstrate that one exists, just as trends in autism prevalence cannot by themselves establish causes.
That limitation was emphasized last year by the Autism Science Foundation in response to comments about CDC surveillance data. The foundation noted that the CDC’s Autism and Developmental Disabilities Monitoring network reviewed education and health records for more than 274,000 children in 16 states to estimate recorded prevalence. Such surveillance can show how often autism is identified in the population; it is not designed to determine what caused autism in a particular child.
A broader fight over federal priorities
Questions about the scope of autism research predate the reported IACC action. ProPublica reported in 2025 on concerns that planned federal priorities could shift money and attention toward environmental-cause research. Autism is generally understood as a complex developmental disability involving genetic, biological and environmental factors, as the Autism Society said in its statement. That complexity makes broad causal claims especially difficult to test and vulnerable to overinterpretation.
If the reported roadmap becomes a basis for agency decisions, its most immediate effect may be to frame future choices about services, research grants and evidence standards. For now, the strongest confirmed point is narrower: the plan is reported to have been adopted as advice. Whether its spending targets, trial proposals or supported-living ideas lead to federal programs will depend on actions that have not yet been announced.
